Loading...
•
Mar 31, 2021
Nkarta Q1 2021 Earnings Report
Nkarta reported financial results for the first quarter ended March 31, 2021.
Key Takeaways
Nkarta reported a net loss of $19.4 million for the first quarter of 2021 and had cash and cash equivalents of $299.7 million as of March 31, 2021. The company expects its current cash and cash equivalents will be sufficient to fund its current operating plan into at least the second half of 2023.
NKX019 IND received FDA clearance; NKX019 patient dosing expected to start in 2H 2021
Protocol amendment to ongoing NKX101 clinical trial adds a second multi-dosing regimen and a shorter waiting period between enrollment of patients
Initial data from NKX101 clinical trial expected by end of 2021
CRISPR Therapeutics collaboration supports early stage cell therapy pipeline with up to three joint programs and enables Nkarta to build gene edits into its own product pipeline
Forward Guidance
Nkarta expects its current cash and cash equivalents will be sufficient to fund its current operating plan into at least the second half of 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...